BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 21060307)

  • 1. An experimental model for the study of well-differentiated and dedifferentiated liposarcoma; deregulation of targetable tyrosine kinase receptors.
    Peng T; Zhang P; Liu J; Nguyen T; Bolshakov S; Belousov R; Young ED; Wang X; Brewer K; López-Terrada DH; Oliveira AM; Lazar AJ; Lev D
    Lab Invest; 2011 Mar; 91(3):392-403. PubMed ID: 21060307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential diagnosis of atypical lipomatous tumor/well-differentiated liposarcoma and dedifferentiated liposarcoma: utility of p16 in combination with MDM2 and CDK4 immunohistochemistry.
    Kammerer-Jacquet SF; Thierry S; Cabillic F; Lannes M; Burtin F; Henno S; Dugay F; Bouzillé G; Rioux-Leclercq N; Belaud-Rotureau MA; Stock N
    Hum Pathol; 2017 Jan; 59():34-40. PubMed ID: 27597521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AXL is a potential therapeutic target in dedifferentiated and pleomorphic liposarcomas.
    May CD; Garnett J; Ma X; Landers SM; Ingram DR; Demicco EG; Al Sannaa GA; Vu T; Han L; Zhang Y; Kivlin CM; Bolshakov S; Kalam AA; Liu J; Zhou F; Broccoli D; Wang WL; Lazar AJ; Pollock RE; Lev D; Torres KE
    BMC Cancer; 2015 Nov; 15():901. PubMed ID: 26573603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-expression of MDM2 and CDK4 in transformed human mesenchymal stem cells causes high-grade sarcoma with a dedifferentiated liposarcoma-like morphology.
    Kim YJ; Kim M; Park HK; Yu DB; Jung K; Song K; Choi YL
    Lab Invest; 2019 Sep; 99(9):1309-1320. PubMed ID: 31160689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and biological significance of CDK4 amplification in well-differentiated and dedifferentiated liposarcomas.
    Italiano A; Bianchini L; Gjernes E; Keslair F; Ranchere-Vince D; Dumollard JM; Haudebourg J; Leroux A; Mainguené C; Terrier P; Chibon F; Coindre JM; Pedeutour F
    Clin Cancer Res; 2009 Sep; 15(18):5696-703. PubMed ID: 19737942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of
    Rekhi B; Karnik N; Agrawal R; Shetty O; Patkar S
    Indian J Pathol Microbiol; 2022; 65(1):65-75. PubMed ID: 35074968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data.
    Binh MB; Sastre-Garau X; Guillou L; de Pinieux G; Terrier P; Lagacé R; Aurias A; Hostein I; Coindre JM
    Am J Surg Pathol; 2005 Oct; 29(10):1340-7. PubMed ID: 16160477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of the 12q amplicons in lipomatous soft tissue tumors by multiplex ligation-dependent probe amplification-based copy number analysis.
    Creytens D; Van Gorp J; Speel EJ; Ferdinande L
    Anticancer Res; 2015 Apr; 35(4):1835-42. PubMed ID: 25862836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased H3K9me3 drives dedifferentiated phenotype via KLF6 repression in liposarcoma.
    Keung EZ; Akdemir KC; Al Sannaa GA; Garnett J; Lev D; Torres KE; Lazar AJ; Rai K; Chin L
    J Clin Invest; 2015 Aug; 125(8):2965-78. PubMed ID: 26193637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of the preadipocyte marker ZFP423 is dysregulated between well-differentiated and dedifferentiated liposarcoma.
    Dang TN; Tiongco RP; Brown LM; Taylor JL; Lyons JM; Lau FH; Floyd ZE
    BMC Cancer; 2022 Mar; 22(1):300. PubMed ID: 35313831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MDM2-p53 in liposarcoma: The need for targeted therapies with novel mechanisms of action.
    Somaiah N; Tap W
    Cancer Treat Rev; 2024 Jan; 122():102668. PubMed ID: 38104352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can MDM2 and CDK4 make the diagnosis of well differentiated/dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours.
    Aleixo PB; Hartmann AA; Menezes IC; Meurer RT; Oliveira AM
    J Clin Pathol; 2009 Dec; 62(12):1127-35. PubMed ID: 19946100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on genomic and molecular landscapes of well-differentiated liposarcoma and dedifferentiated liposarcoma.
    Lu J; Wood D; Ingley E; Koks S; Wong D
    Mol Biol Rep; 2021 Apr; 48(4):3637-3647. PubMed ID: 33893924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adipogenesis induces growth inhibition of dedifferentiated liposarcoma.
    Kim YJ; Yu DB; Kim M; Choi YL
    Cancer Sci; 2019 Aug; 110(8):2676-2683. PubMed ID: 31069877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas.
    Laroche-Clary A; Chaire V; Algeo MP; Derieppe MA; Loarer FL; Italiano A
    J Hematol Oncol; 2017 Jun; 10(1):123. PubMed ID: 28629371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of histological grade of dedifferentiation with clinical outcome in 55 patients with dedifferentiated liposarcomas.
    Dantey K; Schoedel K; Yergiyev O; Bartlett D; Rao UNM
    Hum Pathol; 2017 Aug; 66():86-92. PubMed ID: 28300575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishment and characterization of NCC-DDLPS3-C1: a novel patient-derived cell line of dedifferentiated liposarcoma.
    Tsuchiya R; Yoshimatsu Y; Noguchi R; Ono T; Sei A; Takeshita F; Sugaya J; Fukushima S; Yoshida A; Ohtori S; Kawai A; Kondo T
    Hum Cell; 2021 May; 34(3):1008-1018. PubMed ID: 33677797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The utility of fluorescence in situ hybridization (FISH) in determining DNA damage-inducible transcript 3 (DDIT3) amplification in dedifferentiated liposarcomas - an important diagnostic pitfall.
    Kuczkiewicz-Siemion O; Wiśniewski P; Dansonka-Mieszkowska A; Grabowska-Kierył M; Olszewska K; Goryń T; Prochorec-Sobieszek M; Rutkowski P; Szumera-Ciećkiewicz A
    Pathol Res Pract; 2021 Sep; 225():153555. PubMed ID: 34325315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chromosome-12 copy number alterations and MDM2, CDK4 and TP53 expression in soft tissue liposarcoma.
    Segura-Sánchez J; González-Cámpora R; Pareja-Megia MJ; García-Escudero A; Galera-Ruiz H; López-Beltrán A
    Anticancer Res; 2006; 26(6C):4937-42. PubMed ID: 17214366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical value of fluorescence
    Wang W; Li X; Liu P; Dong Y
    Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 55(2):228-233. PubMed ID: 37042132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.